DAE HWA Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DAE HWA Pharm makes prescription and over-the-counter medicines, finished pharmaceutical products used by patients and dispensed through hospitals, clinics, and pharmacies in South Korea.
It supplies its products to the domestic healthcare market and is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company is currently profitable, though its revenue has declined on a year-over-year basis.
Summary is AI-generated and may contain errors · figures from DART filings
DAE HWA Pharm in five facts
What does DAE HWA Pharm do?
DAE HWA Pharm makes prescription and over-the-counter medicines, finished pharmaceutical products used by patients and dispensed through hospitals, clinics, and pharmacies in South Korea.
Where is DAE HWA Pharm listed and in which sector?
DAE HWA Pharm (Korean name: 대화제약) trades under KRX code 067080 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is DAE HWA Pharm?
Its market capitalisation was US$144.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DAE HWA Pharm's latest annual revenue and operating profit?
For fiscal year 2025, DAE HWA Pharm reported revenue of US$108M, operating profit of US$2.4M and net income of US$1.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 4.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 16
- DisclosureOct 12
- Report on securities held by executives/major shareholdersSep 22
- Report on securities held by executives/major shareholdersSep 22
- [Amended] Supply contract terminated
DAE HWA Pharm updated a previously disclosed supply contract, now worth US$8.66M, about 8.59% of its recent annual revenue, running through Oct 2026.
Supply contract · Sep 18 · 2 versions - Supply contract terminated
DAE HWA Pharm disclosed a supply contract with Eucogen Pharma Sdn Bhd, worth US$7.19M, about 6.95% of its recent annual revenue, running through Sep 2026.
Supply contract · Sep 7 - Cash/in-kind dividend decision (quarterly dividend)
DAE HWA Pharm declared a cash dividend of US$0.04 per share, equal to about 0.5% of the recent share price.
Dividend · Aug 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
DAE HWA Pharm reported consolidated results for FY2025: revenue of US$95.3M (−4.2% year on year), operating profit of US$2.11M (−52.8% year on year) and net income of US$1.55M (+180.7% year on year).
Earnings · Mar 16 - Treasury share disposal: results reportTreasury Shares · Mar 3
- Decision to acquire shares/equity in another company
DAE HWA Pharm disclosed an acquisition of an individual, worth US$7.58M.
M&A · Feb 26 - Material event report (treasury share disposal)
DAE HWA Pharm disclosed a plan to sell treasury shares worth US$7.58M, about 4.9% of its market value.
Treasury Shares · Feb 26 - Cash/in-kind dividend decision
DAE HWA Pharm declared a cash dividend of US$0.07 per share.
Dividend · Feb 13